

providing a cyclic lipopeptide, a salt of the lipopeptide, an ester of the lipopeptide, or a mixture thereof;

contacting said product with the cyclic lipopeptide, salt of the lipopeptide, ester of the lipopeptide, or mixture thereof as an inactivating agent, at room temperature for 30 minutes up to 2 hours,

wherein the agent is added to said product at a concentration of 1-100 μ M and viral titer is reduced by a factor of $>10^4$ through the direct inactivation of any lipid-enveloped viruses present in said product by the agent.

18. (Amended) The method of claim 1, wherein the cell-free biological product is selected from the group consisting of products isolated from blood, and biotechnological pharmaceutical products consisting of human proteins.

19. (Amended) The method of claim 18, wherein the product isolated from blood is a vaccine.